Target intelligence / Profile preview

Glutamate receptor subunit 5 (also known as Glutamate receptor ionotropic, kainate 2) (GluR5 (current nomenclature: GRIK2))

Target
GluR5 (current nomenclature: GRIK2)
Molecular classification
Ion channel, Receptor, Ligand-gated ion channel, Ionotropic glutamate receptor (iGluR), Kainate receptor family (kainate subfamily of iGluRs)
01

Overview

Glutamate receptor subunit 5 (GluR5, now formally GRIK2) is a protein subunit that assembles with others to form kainate-type ionotropic glutamate receptors. These receptors are ligand-gated cation channels primarily located in the central nervous system, where they mediate fast excitatory neurotransmission via binding to glutamate, the principal excitatory neurotransmitter in the brain. GluR5-containing receptors play essential roles in synaptic plasticity and modulation of neurotransmitter release, and have been implicated in diverse physiological processes as well as diseases such as epilepsy, neurodegeneration, and psychiatric disorders. Structurally, GluR5 shares a common architecture with other iGluRs, forming tetramers with a central ion channel pore; binding of agonists or antagonists to the extracellular ligand-binding domain induces conformational changes that regulate channel gating and neuronal excitability[1][3][7][5]. Selective antagonists, such as UBP302 and UBP310, provide tools to dissect specific functional roles of GluR5-containing receptors and offer potential for targeted therapeutics, though adverse CNS effects present a major challenge[1].

Other names
GRIK2 (current gene symbol)Glutamate receptor, ionotropic, kainate 2KA2GRIK5 (historically imprecise but sometimes used in literature; correct: GRIK2)
02

Mechanism of action

Modulation of neuronal excitability through gated cation (Na+, K+, to lesser degree Ca2+) flux - Drugs may act as competitive antagonists (e.g., UBP302, UBP310) or non-competitive antagonists, inhibiting synaptic transmission through channel block or allosteric effects[1] - Agonists (such as kainic acid) promote receptor activation and excitatory signaling

03

Biological functions

Mediates excitatory synaptic transmissionSynaptic plasticitySignal transduction in central nervous system neuronsModulation of neurotransmitter release
04

Disease associations

Neurodegenerative diseaseEpilepsy and seizure disordersPsychiatric disorders (including schizophrenia and mood disorders)Other neurological diseases
05

Safety considerations

Targeting GluR5 is associated with risk of seizures, excitotoxicity, and neuropsychiatric side effects due to broad roles in excitatory neurotransmissionRisk of off-target CNS effects, as related iGluRs are widely expressed and involved in cognitive and behavioral processes
06

Interacting drugs

Topiramate (nonselective antagonist activity)

3 more in the full profile.

07

Biomarkers

Expression levels may be explored as a biomarker in certain epilepsy or neurodegenerative disease studies, but no widely validated biomarker role established

Beyond the preview

Go deeper on Glutamate receptor subunit 5 (also known as Glutamate receptor ionotropic, kainate 2) (GluR5 (current nomenclature: GRIK2)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glutamate receptor subunit 5 (also known as Glutamate receptor ionotropic, kainate 2) (GluR5 (current nomenclature: GRIK2)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call